Zhongze Therapeutics

Executive Summary

Zhongze Therapeutics is a clinical-stage Chinese biotech company founded in 2020, specializing in innovative treatments for psychiatric disorders such as schizophrenia and major depressive disorder. Its lead asset, ZZ6398, is a potential first-in-class antipsychotic designed to address multiple symptom domains of schizophrenia, including positive, negative, and cognitive symptoms. The company operates with a multi-mechanism pipeline strategy to tackle the significant unmet needs in psychiatry, where existing therapies often have limited efficacy or undesirable side effects. As a private company with 10-50 employees, Zhongze is advancing its pipeline through Phase 1 studies, positioning itself in a high-demand therapeutic area with substantial market potential.

Upcoming Catalysts (preview)

• Q4 2026Completion of Phase 1 trial for ZZ6398 and data readout70% success
• Q2 2027Initiation of Phase 2 study for ZZ639860% success
• TBDPotential strategic partnership or licensing deal for ex-China rights40% success